Bausch & Lomb Corp (BLCO) Stock Price, Quote & News

Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeut...

Industry: Medical Instruments & Supplies

Sector: Healthcare

Phone: 905 695 7700

Website: www.bausch.com

Address:

520 Applewood Crescent, Vaughan, Canada

TickrTalk0007 Jul. 29 at 1:36 PM

$BLCO stock down 5%…. That’s how them apples are… company needs money- offering or debt (on top of already existing debt)🥶 Brent is going to quit

0 · Reply

EarningsInsider Jul. 29 at 1:31 PM

https://www.marketbeat.com/earnings/reports/2026-7-29-bausch-lomb-co-stock/ $BLCO Bausch + Lomb Earnings Transcript

0 · Reply

Rpate Jul. 29 at 1:18 PM

$BLCO Q2 2026 margin is 17.6% Q2 2025 margin was 15% FCF is positive. Great result in-line as expected.

0 · Reply

StocktwitsEarnings Jul. 29 at 1:08 PM

$BLCO Q2 '26 Earnings Results & Recap Bausch + Lomb raised its full-year 2026 revenue guidance to a range of $5.440B $5.540B and adjusted EBITDA excluding acquired IPR&D to a range of $1.025B $1.075B.

0 · Reply

Coolhat1 Jul. 29 at 11:21 AM

$BLCO @TickrTalk0007 how about them apples

1 · Reply

TraderJoe65 Jul. 23 at 1:19 PM

$LENZ is $BLCO going to buy LENZ or what

0 · Reply

TickrTalk0007 Jul. 11 at 12:34 PM

$BLCO worthless pipeline…Manisha did nothing right. Brent is going to be stuck for a while. Won’t be surprised if he takes paternity leave 🤣

0 · Reply

DoubleUpwithChuck Jul. 10 at 1:31 AM

$BLCO did they get a new ticker? Apparently i own this somewhere

0 · Reply

StocktwitsNews Jul. 9 at 11:10 PM

BLCO Stock Drops After-Hours — Bausch + Lomb Halts Glaucoma Eye Drop Program After Trial Failure $BLCO $DFAX https://stocktwits.com/news/equity/markets/blco-stock-drops-after-hours-after-company-halts-glaucoma-eye-drop-program/cZmYXNTR7Fb

0 · Reply

notreload_ai Jul. 9 at 9:05 PM

$BLCO announced that its Phase 2 study of BL1107 eye drops in glaucoma missed the primary endpoint. The company will discontinue the topical program but continue advancing a sustained-release implant for geographic atrophy. https://notreload.xyz/xy/blco-discontinues-bl1107-glaucoma-eye-drops/

0 · Reply

Bausch + Lomb price target raised to $23 from $21 at UBS

Jul 29, 2026, 8:00 AM EDT - 4 days ago

Bausch + Lomb Earnings Call Transcript: Q2 2026

Jul 29, 2026, 8:00 AM EDT - 4 days ago

Bausch + Lomb Earnings release: Q2 2026

Jul 29, 2026, 8:00 AM EDT - 4 days ago

Bausch + Lomb Slides: Q2 2026

Jul 29, 2026, 8:00 AM EDT - 4 days ago

Bausch + Lomb Quarterly report: Q2 2026

Jul 29, 2026, 7:57 AM EDT - 4 days ago

Bausch + Lomb Upgrades Full-Year Outlook on Strong Quarter

2026-07-29T11:06:34.000Z - 4 days ago

Bausch + Lomb reports Q2 adjusted EPS 15c, consensus 16c

2026-07-29T11:05:49.000Z - 4 days ago

Bausch + Lomb raises FY26 revenue view to $5.440B-$5.540B from $5.420B-$5.520B

Jul 29, 2026, 6:58 AM EDT - 4 days ago

Bausch + Lomb Delivers Broad-Based Second-Quarter Growth, Raises Full-Year 2026 Guidance

2026-07-28T12:06:29.000Z - 5 days ago

Bausch + Lomb initiated with a Buy at UBS

2026-07-28T10:46:22.000Z - 5 days ago

Bausch + Lomb initiated with a Buy at UBS

2026-07-16T11:05:10.000Z - 17 days ago

Bausch + Lomb launches EyeGility Inserter in U.S.

Jul 16, 2026, 7:00 AM EDT - 17 days ago

Bausch + Lomb Launches EyeGility™ Inserter Preloaded IOL Delivery System in the United States

2026-07-09T20:35:22.000Z - 23 days ago

Bausch + Lomb says Phase 2 study of BL1107 did not achieve primary endpoint

Jul 9, 2026, 4:30 PM EDT - 23 days ago

Bausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate

2026-07-09T11:05:11.000Z - 24 days ago

Bausch + Lomb introduces Orphia AI-powered digital health platform

Jul 9, 2026, 7:00 AM EDT - 24 days ago

Bausch + Lomb Introduces Orphia™, an AI-Powered Digital Health Platform Built to Return Physicians to Patient Care

2026-07-08T10:15:21.000Z - 25 days ago

Bausch + Lomb price target raised to $21 from $19 at Citi

2026-07-06T12:46:45.000Z - 27 days ago

Bausch + Lomb price target raised to $17 from $16 at Evercore ISI

Jul 6, 2026, 7:15 AM EDT - 27 days ago

Bausch + Lomb Will Release Second-Quarter 2026 Financial Results on July 29

2026-07-01T11:11:48.000Z - 4 weeks ago

Bausch + Lomb announces new findings from third State of Dry Eye survey

Jul 1, 2026, 7:00 AM EDT - 4 weeks ago

New Bausch + Lomb Data Show that Addressing Dry Eye Symptoms is Associated with Improved Quality of Life, Including Lower Anxiety and Increased Self-Confidence

Jun 9, 2026, 1:20 PM EDT - 7 weeks ago

Bausch + Lomb Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 1, 2026, 1:00 PM EDT - 2 months ago

Bausch + Lomb Transcript: R&D Day 2026

Jun 1, 2026, 1:00 PM EDT - 2 months ago

Bausch + Lomb Slides: FY 2026

Jun 1, 2026, 6:59 AM EDT - 2 months ago

Bausch + Lomb Launches Blink® Triple Care Preservative Free Lubricant Eye Drops in the United States

May 21, 2026, 7:15 AM EDT - 2 months ago

Bausch + Lomb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

May 20, 2026, 4:49 PM EDT - 2 months ago

Bausch + Lomb Announces 2026 Annual Meeting of Shareholder Results

May 20, 2026, 10:30 AM EDT - 2 months ago

Bausch + Lomb Transcript: AGM 2026

2026-05-19T11:10:10.000Z - 2 months ago

Bausch + Lomb announces U.S. launch of PreserVision AREDS3

2026-05-07T14:16:04.000Z - 3 months ago

Bausch + Lomb launches Bi-Blade+ dual-port vitrectomy cutter in Europe

May 6, 2026, 7:15 AM EDT - 3 months ago

Bausch + Lomb Announces Second R&D “Teach-in” Webinar

2026-04-30T16:45:33.000Z - 3 months ago

Bausch + Lomb price target lowered to $16 from $17 at Evercore ISI

2026-04-30T14:24:47.000Z - 3 months ago

Bausch + Lomb price target lowered to $16 from $18 at Deutsche Bank

2026-04-30T11:48:27.000Z - 3 months ago

Bausch + Lomb price target lowered to C$19 from C$21 at Citi

Apr 30, 2026, 7:00 AM EDT - 3 months ago

Bausch + Lomb to Feature More Than 40 Scientific Studies at the 2026 Association for Research in Vision and Ophthalmology Annual Meeting

Apr 29, 2026, 8:00 AM EDT - 3 months ago

Bausch + Lomb Earnings Call Transcript: Q1 2026

Apr 29, 2026, 8:00 AM EDT - 3 months ago

Bausch + Lomb Earnings release: Q1 2026

Apr 29, 2026, 8:00 AM EDT - 3 months ago

Bausch + Lomb Slides: Q1 2026

Apr 29, 2026, 8:00 AM EDT - 3 months ago

Bausch + Lomb Quarterly report: Q1 2026

2026-04-29T11:55:45.000Z - 3 months ago

Bausch + Lomb reports Q1 adjusted EPS 5c, consensus 5c

2026-04-29T11:51:53.000Z - 3 months ago

Bausch + Lomb raises FY26 revenue view to $5.420B-$5.530B from $5.375B-$5.475B

Apr 29, 2026, 6:58 AM EDT - 3 months ago

Bausch + Lomb Announces First-Quarter 2026 Results, Raises Guidance Based on Strong Performance and Positive Outlook

2026-04-23T11:15:36.000Z - 3 months ago

Bausch + Lomb announces narrative review on certain B vitamins

Apr 22, 2026, 7:15 AM EDT - 3 months ago

Bausch + Lomb Releases 2025 Sustainability Impact Report

2026-04-16T11:23:23.000Z - 3 months ago

Bausch + Lomb reports nearly 725k lbs. of eye care materials recycled

Apr 16, 2026, 7:00 AM EDT - 3 months ago

Bausch + Lomb Reports Nearly 725,000 Pounds of Contact Lens, Lens Care and Eye Care Materials Collected and Recycled Through ONE By ONE Recycling Program

Apr 10, 2026, 8:00 AM EDT - 4 months ago

Bausch + Lomb Proxy statement: Proxy filing

$Bausch + Lomb Announces New Scientific Data, Educational Events at the American Society of Cataract and Refractive Surgery Annual Meeting$

Apr 6, 2026, 7:00 AM EDT - 4 months ago

Bausch + Lomb Announces New Scientific Data, Educational Events at the American Society of Cataract and Refractive Surgery Annual Meeting

Mar 30, 2026, 7:15 AM EDT - 4 months ago

Bausch + Lomb Will Release First-Quarter 2026 Financial Results on April 29

Mar 23, 2026, 1:30 PM EDT - 4 months ago

Bausch + Lomb Transcript: Status update

Mar 23, 2026, 1:30 PM EDT - 4 months ago

Bausch + Lomb Press release: Status update

Mar 23, 2026, 1:30 PM EDT - 4 months ago

Bausch + Lomb Slides: Status update

Mar 23, 2026, 7:00 AM EDT - 4 months ago

Bausch + Lomb Announces Positive 24-Month U.S. Data on the ELIOS™ System for Treatment of Glaucoma

Mar 13, 2026, 9:00 AM EDT - 5 months ago

Bausch + Lomb Corporation Investigated by the Portnoy Law Firm

Mar 9, 2026, 7:15 AM EDT - 5 months ago

Bausch + Lomb Launches R&D “Teach-in” Webinar Series

Feb 24, 2026, 7:00 AM EST - 5 months ago

Ophthalmology and Therapy Publishes Findings Showing Lifestyle-Driven Rise in Ocular Redness and Differentiated Role of LUMIFY®

Feb 18, 2026, 8:00 AM EST - 5 months ago

Bausch + Lomb Earnings Call Transcript: Q4 2025

Feb 18, 2026, 8:00 AM EST - 5 months ago

Bausch + Lomb Annual report: Q4 2025

Feb 18, 2026, 8:00 AM EST - 5 months ago

Bausch + Lomb Earnings release: Q4 2025

Feb 18, 2026, 8:00 AM EST - 5 months ago

Bausch + Lomb Slides: Q4 2025

Feb 18, 2026, 6:58 AM EST - 5 months ago

Bausch + Lomb Announces Fourth-Quarter and Full-Year 2025 Results, Provides 2026 Guidance

Jan 20, 2026, 7:15 AM EST - 6 months ago

Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2025 Financial Results on Feb. 18

Jan 12, 2026, 4:30 PM EST - 7 months ago

Bausch + Lomb Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 4:30 PM EST - 7 months ago

Bausch + Lomb Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 7:00 AM EST - 7 months ago

Bausch + Lomb Partners with Glaucoma Research Foundation and The Glaucoma Foundation to Address a Leading Cause of Irreversible Blindness in the U.S.

Jan 2, 2026, 4:30 PM EST - 7 months ago

Bausch + Lomb Completes Refinancing of Outstanding Term B Loans

Dec 23, 2025, 7:30 AM EST - 7 months ago

Bausch + Lomb to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Dec 17, 2025, 4:30 PM EST - 8 months ago

Bausch + Lomb Announces Two Board of Directors Appointments

Dec 12, 2025, 4:48 PM EST - 8 months ago

Bausch + Lomb Announces Refinancing of Outstanding Term B Loans

Dec 3, 2025, 9:00 AM EST - 8 months ago

Bausch + Lomb Transcript: Citi Annual Global Healthcare Conference 2025

Nov 18, 2025, 4:30 PM EST - 9 months ago

Bausch + Lomb to Participate in Citi Global Healthcare Conference

Nov 13, 2025, 8:30 AM EST - 9 months ago

Bausch + Lomb Transcript: Investor Day 2025

Nov 13, 2025, 8:30 AM EST - 9 months ago

Bausch + Lomb Slides: FY 2025

Nov 10, 2025, 6:59 AM EST - 9 months ago

Bausch + Lomb Reports More Than 690,000 Pounds of Contacts Lens, Lens Care and Eye Care Materials Collected Through ONE By ONE Recycling Program

Oct 29, 2025, 8:00 AM EDT - 9 months ago

Bausch + Lomb Earnings Call Transcript: Q3 2025

Oct 29, 2025, 8:00 AM EDT - 9 months ago

Bausch + Lomb Quarterly report: Q3 2025

Oct 29, 2025, 8:00 AM EDT - 9 months ago

Bausch + Lomb Earnings release: Q3 2025

Oct 29, 2025, 8:00 AM EDT - 9 months ago

Bausch + Lomb Slides: Q3 2025

Oct 29, 2025, 6:58 AM EDT - 9 months ago

Bausch + Lomb Announces Third-Quarter 2025 Results

Oct 19, 2025, 8:00 PM EDT - 10 months ago

Activist Jana Takes Stake in Cooper, a Maker of Medical Devices

COO

Sep 29, 2025, 7:15 AM EDT - 10 months ago

Bausch + Lomb Will Release Third-Quarter 2025 Financial Results on Oct. 29 and Hold Investor Day on Nov. 13

Sep 8, 2025, 7:45 AM EDT - 11 months ago

Bausch + Lomb Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 8, 2025, 7:00 AM EDT - 11 months ago

Bausch + Lomb Launches ASANA™ Gas Permeable Lenses in the United States

Aug 18, 2025, 5:01 PM EDT - 1 year ago

Bausch + Lomb Announces Board Changes

Aug 14, 2025, 7:15 AM EDT - 1 year ago

Bausch + Lomb to Participate in Upcoming Investor Conferences

Jul 30, 2025, 8:00 AM EDT - 1 year ago

Bausch + Lomb Earnings Call Transcript: Q2 2025

Jul 30, 2025, 8:00 AM EDT - 1 year ago

Bausch + Lomb Quarterly report: Q2 2025

Jul 30, 2025, 8:00 AM EDT - 1 year ago

Bausch + Lomb Earnings release: Q2 2025

Jul 30, 2025, 8:00 AM EDT - 1 year ago

Bausch + Lomb Slides: Q2 2025

Jul 30, 2025, 6:57 AM EDT - 1 year ago

Bausch + Lomb Announces Second-Quarter 2025 Results

Jul 1, 2025, 7:00 AM EDT - 1 year ago

Bausch + Lomb Combines Patient Voices and New Survey Insights to Combat Persistent Misconceptions about Dry Eye

Jun 30, 2025, 6:58 AM EDT - 1 year ago

Bausch + Lomb Will Release Second-Quarter 2025 Financial Results on July 30 and Hold Investor Day on Nov. 13

Jun 18, 2025, 4:30 PM EDT - 1 year ago

Bausch + Lomb Announces Pricing of Upsized Senior Secured Notes Offering

Jun 10, 2025, 8:48 AM EDT - 1 year ago

Bausch + Lomb Announces Launch of Senior Secured Notes Offering and Refinancing of Credit Agreement

TickrTalk0007 Jul. 29 at 1:36 PM

$BLCO stock down 5%…. That’s how them apples are… company needs money- offering or debt (on top of already existing debt)🥶 Brent is going to quit

0 · Reply

EarningsInsider Jul. 29 at 1:31 PM

https://www.marketbeat.com/earnings/reports/2026-7-29-bausch-lomb-co-stock/ $BLCO Bausch + Lomb Earnings Transcript

0 · Reply

Rpate Jul. 29 at 1:18 PM

$BLCO Q2 2026 margin is 17.6% Q2 2025 margin was 15% FCF is positive. Great result in-line as expected.

0 · Reply

StocktwitsEarnings Jul. 29 at 1:08 PM

0 · Reply

Coolhat1 Jul. 29 at 11:21 AM

$BLCO @TickrTalk0007 how about them apples

1 · Reply

TraderJoe65 Jul. 23 at 1:19 PM

$LENZ is $BLCO going to buy LENZ or what

0 · Reply

TickrTalk0007 Jul. 11 at 12:34 PM

$BLCO worthless pipeline…Manisha did nothing right. Brent is going to be stuck for a while. Won’t be surprised if he takes paternity leave 🤣

0 · Reply

DoubleUpwithChuck Jul. 10 at 1:31 AM

$BLCO did they get a new ticker? Apparently i own this somewhere

0 · Reply

StocktwitsNews Jul. 9 at 11:10 PM

0 · Reply

notreload_ai Jul. 9 at 9:05 PM

0 · Reply

TickrTalk0007 Jul. 8 at 2:24 PM

$BLCO has had the worst pipeline in years. They’re pumping meibo but it’s just a $20 drop in Europe that $BLCO is selling for $600 to US tax payers and issuance…someone needs to investigate this

0 · Reply

DidYouReadThis Jul. 7 at 6:50 PM

$OTLK vs $BLCO, How many years do you think it might take $OTLK to have a higher market cap than $BLCO? Good luck to $OTLK for PDUFA 7/29/26 #WetAMD #Bevacizumab! Bausch + Lomb Corp market cap about 6.13B. Outlook Therapeutics market cap: about 226.61 million.

0 · Reply

Coolhat1 Jul. 2 at 11:32 PM

$BLCO someday

1 · Reply

Coolhat1 Jul. 2 at 3:15 PM

$BHC $BLCO going up

0 · Reply

Coolhat1 Jun. 29 at 8:47 PM

$BHC if anyone has a brain at $COO they would merge with $BLCO and hire Brent as ceo to take over and have him sell it for a large premium. Look at what he did with forest lab allergen and actavis. Merged all of them

1 · Reply

TickrTalk0007 Jun. 15 at 3:39 AM

$BLCO worthless company with sh*tty products. Fire the BD and Corp strategy team

0 · Reply

TraderJoe65 Jun. 10 at 2:58 AM

$LENZ in what world does $BLCO not buy this outright

2 · Reply

Aldinho_lbk May. 28 at 2:43 PM

$OTLK the fact institutional investors are on board after learning FDA approval towards "final labeling", directors have more skin in the game, and Baush and Lomb $BLCO is the potential candidate according to Claude AI, makes this stock a preferred investment for this upcoming month.

0 · Reply

CgI86 May. 28 at 6:49 AM

$BHC $BLCO $COO

0 · Reply

Aldinho_lbk May. 27 at 8:25 PM

$OTLK according to Claude, the likelihood of institutions acquiring $OTLK shares in the open market are higher because "undervalue". Baush and Lomb $BLCO may be the partnership needed.

0 · Reply

Aldinho_lbk May. 26 at 4:15 PM

$OTLK people taking a sip on speculative take over, with Roche $RHHBY as potential candidate. Allow me to differ. ALCON $ALC and Baush Lamb $BLCO are more suitable partners here in the USA, even for a M&A...

1 · Reply

NVDAMillionaire May. 13 at 8:29 PM

$BLCO Great piece that accurately captures BLCO's current position. So if you want to refresh your understanding of BLCO or learn about BLCO for the first time, this is essential reading. https://everyticker.com/quote/BLCO/analysis/margin-inflection-meets-portfolio-diversification-at-bausch-lomb-nyse-blco

0 · Reply

Market Cap	6.04B
Revenue (ttm)	5.10B
Net Income (ttm)	-360.00M
EPS (ttm)	N/A
PE Ratio	22.96
Forward PE	20.62
Profit Margin	-7.06%
Debt to Equity Ratio	0.79

Volume	469,200
Avg Vol	444,310
Day's Range	N/A - N/A
Shares Out	357.06M
Stochastic %K	93%
Beta	0.56
Analysts	Sell
Price Target	$18.85